Background Some disease-modifying agents commonly used to treat patients with
rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are�…

The COVID-19 pandemic has resulted in more than 2 million deaths globally. Two
interconnected stages of disease are generally recognised; an initial viral stage and a�…

The recent novel coronavirus disease (COVID-19) outbreak, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is seeing a rapid increase in infected�…

Objectives: The causative agent for coronavirus disease 2019, severe acute respiratory
syndrome coronavirus 2, appears exceptional in its virulence and immunopathology. In�…

After analyzing the immune characteristics of patients with severe coronavirus disease 2019
(COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with�…

Recurrences of COVID-19 were observed in a patient with long-term usage of
hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of�…

Severe coronavirus disease 2019 (COVID-19) is characterized by pneumonia, lymphopenia,
exhausted lymphocytes and a cytokine storm. Significant antibody production is observed;�…

Summary Coronavirus disease 2019 (COVID‐19) is a clinical syndrome caused by the
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus. Patients can be�…

Objective To analyze clinical characteristics and outcome of COVID-19 patients with
underlying rheumatic diseases (RD) on immunosuppressive agents. Method A case series�…

SARS-Cov-2 virus has attracted a lot of attention globally, due to the autoimmune and
inflammatory processes that were observed during the development of Covid-19 disease�…